Open AccessDasatinib Induced Cardiac Tamponade- A Rare Association
Author(s) -
Sushant Wattal
Publication year - 2017
Publication title -
journal of clinical and diagnostic research
Language(s) - Uncategorized
Resource type - Journals
eISSN - 2249-782X
pISSN - 0973-709X
DOI - 10.7860/jcdr/2017/24633.9418
Subject(s) - dasatinib , medicine , imatinib , cardiac tamponade , pericardial effusion , tyrosine kinase inhibitor , tyrosine kinase , myeloid leukemia , imatinib mesylate , gastroenterology , receptor , cancer
Drug induced cardiac tamponade is rare. Therapy for imatinib resistant Chronic Myeloid Leukaemia (CML) is an emerging challenge in clinical haematology. For such cases treatment with second line tyrosine kinase inhibitors like dasatinib has resulted in improved outcomes. Dasatinib is a second line BCR-ABL tyrosine kinase inhibitor used in the treatment of Imatinib resistant or Imatinib intolerant CML. Dasatinib has been reported to cause severe pericardial effusions in 1% of all patients in clinical studies. We report here a case of Dasatinib induced cardiac tamponade in whom all other causes of pericardial effusion were excluded and whose clinical symptoms as well as effusion showed no recurrence one month after the drug was stopped.